Antibody research field has dramatically revolutionized the pharmaceutical industry for diagnosis and therapeutic applications. Ever since after the approval of first monoclonal antibody by US-FDA, researchers have been extensively working on this new class of drugs called antibodies. Owing to its inexpensive, fast production of no ethical concern, IgY from avian source i.e., chicken-IgY has attracted many researchers. Nevertheless, the combination of deploying nanoparticle and IgY-technology has a great potential in making tremendous impact in combating the issues of biosensing and antibody delivery. The so-called nano-immunotherapy, that uses nanoparticles as a carrier to safely and effectively transport IgY antibodies to the target region, may be the most cutting-edge, sophisticated, effective, and best method to address antibody delivery-related problems. Utilizing the proper moieties, functionalized nanomaterials can help improve the localization of antibodies at a specific site, thereby reducing off-targeting problems, protect them from enzyme-mediated degradation, lessen side effects, and decrease the frequency of dosage by high loadings in a single dose. Overall, this review presents the so-far postulated frameworks on the usage of nanomaterials with IgY for diagnostic and therapeutic applications thereby discussing the immediate need in shifting the paradigm of employing nano-IgY technology to set a benchmark in healthcare industry.